Galmed Pharmaceuticals (GLMD)
Develops Aramchol candidates and CG-100 for colorectal surgery.
Something off on this page? Send us feedback.
Develops Aramchol drug candidates and the CG-100 colorectal-surgery device, targeting future licensing and hospital sales while depending on outsourced development, clinical and regulatory progress, reimbursement, and surgeon adoption.
Develops Aramchol, a partial SCD1 modulator formerly studied in MASH and now under preclinical investigation as an adjunct in GI oncology, alongside CG-100, a temporary intraluminal device intended to protect colorectal anastomoses. The portfolio also includes early cardiac-targeted and neurological formulations of Aramchol, while Amilo-5MER is being offered for out-licensing.
Coordinates internal development with academic research partners and third parties for drug manufacturing and clinical trials. CG-100 commercialization is planned through hospital sales and distributors in Europe and Israel; US sales require regulatory approval. Revenue generation depends on clinical progress, reimbursement, hospital purchasing, and surgeon training and adoption.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $15.5M · Total debt $0 · Total assets $16.0M · Shareholders' equity $13.9M
- Revenue
- $0
- Operating income
- −$2.0M
- Net income
- −$1.9M
No dividends on record.
1.03M ADS (1 ADS = 25 ordinary shares) as of Sep 3, 2026 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
683 Capital Management, LLCInstitution | —3.80% of class, as filed | — | 13G/Afiled Feb 13, 2020 ↗ |
BVF Inc.Strategic | —8.40% of class, as filed | — | 13G/Afiled Feb 12, 2021 ↗ |
Chaim HurvitzInsider | —7.30% of class, as filed | — | 13G/Afiled Jan 26, 2018 ↗ |
Investors LLCStrategic | —1.40% of class, as filed | — | 13G/Afiled Jan 27, 2022 ↗ |
Wilmot B. HarkeyInsider | —1.20% of class, as filed | — | 13G/Afiled Feb 14, 2022 ↗ |
| See all 6 → | |||
13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Madrigal Pharmaceuticals
MASH market leader with FDA-approved Rezdiffra.
- Novo Nordisk (ADR)
FDA-approved Wegovy brings scaled GLP-1 competition to MASH.
- Viking Therapeutics
Late-stage metabolic-liver drug rivalry through VK2809.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Galmed Pharmaceuticals | $4.06 | +0.50% | $4.3M | — | — | — | — |
| Madrigal Pharmaceuticals | $546.41 | +1.43% | $12.64B | — | — | 9.8 | +71.2% |
| Novo Nordisk (ADR) | $47.45 | +1.49% | $207.69B | 11.5 | 18.9 | 4.1 | +0.0% |
| Viking Therapeutics | $32.98 | −1.55% | $3.91B | — | — | — | — |
| Median | 11.5 | 18.9 | 7.0 | +35.6% |